Views & Analysis Data: underpinning health R&D Big data initiatives positioning the UK as a desirable location for R&D.
News Rare leukaemia drug gets funding for phase 2 trial Investment fund kick-starts phase 2 trial in CMML
News Innate and BMS' immunotherapy fails in phase 2 trial French biotech developing cancer immunotherapy with BMS.
News Kyowa Kirin to expand UK headquarters despite Brexit Other Japanese firms could scale back UK investment.
News Invest in NHS to boost life sciences, says pharma body Make NHS best place to research and launch drugs, says ABPI.
News BMS suffers further setback in lung cancer No fast approval for immunotherapy combo in first line use.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
